$GPCR
Structure Therapeutics Inc

2023 Q4 Form 10-Q Financial Statement

#000155837023019203 Filed on November 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.95M $8.630M $11.77M
YoY Change 138.29% -26.69% 125.6%
% of Gross Profit
Research & Development $20.04M $17.52M $27.83M
YoY Change 139.74% -37.07% 44.93%
% of Gross Profit
Depreciation & Amortization $72.00K $79.00K $205.0K
YoY Change 0.0% -61.46% 3316.67%
% of Gross Profit
Operating Expenses $30.99M $26.15M $39.61M
YoY Change 139.23% -33.99% 62.17%
Operating Profit -$26.15M -$12.69M
YoY Change 105.98%
Interest Expense $6.179M $2.688M $356.0K
YoY Change 585.79% 655.06% -394.21%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$24.82M -$23.46M -$39.25M
YoY Change 105.85% -40.24% 59.92%
Income Tax -$312.0K $405.0K $197.0K
% Of Pretax Income
Net Earnings -$24.50M -$23.86M -$40.96M
YoY Change 106.34% -41.74% 44.56%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21 -$1.27
Diluted Earnings Per Share -$0.18 -$0.21 -$0.37
COMMON SHARES
Basic Shares Outstanding 139.2M 114.8M 9.780M
Diluted Shares Outstanding 114.9M 9.780M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $467.3M $205.4M $102.8M
YoY Change 414.44% 99.92%
Cash & Equivalents $129.8M $50.64M $28.09M
Short-Term Investments $337.5M $154.8M $74.66M
Other Short-Term Assets $6.285M $4.535M $2.016M
YoY Change 179.58% 124.95%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $473.6M $210.0M $104.8M
YoY Change 408.77% 100.41%
LONG-TERM ASSETS
Property, Plant & Equipment $3.228M $2.408M $1.370M
YoY Change 149.65% 75.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $45.00K $350.0K $2.269M
YoY Change -98.7% -84.57%
Total Long-Term Assets $8.409M $6.411M $3.639M
YoY Change 76.81% 76.17%
TOTAL ASSETS
Total Short-Term Assets $473.6M $210.0M $104.8M
Total Long-Term Assets $8.409M $6.411M $3.639M
Total Assets $482.0M $216.4M $108.4M
YoY Change 392.63% 99.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.742M $3.319M $5.703M
YoY Change -21.09% -41.8%
Accrued Expenses $18.53M $14.75M $6.234M
YoY Change 190.74% 136.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.74M $20.09M $12.23M
YoY Change 90.16% 64.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $298.0K $281.0K $115.0K
YoY Change 144.35%
Total Long-Term Liabilities $298.0K $281.0K $115.0K
YoY Change 144.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.74M $20.09M $12.23M
Total Long-Term Liabilities $298.0K $281.0K $115.0K
Total Liabilities $29.05M $23.41M $12.34M
YoY Change 123.3% 89.61%
SHAREHOLDERS EQUITY
Retained Earnings -$206.6M -$182.1M
YoY Change 76.65%
Common Stock $14.00K
YoY Change 1300.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $453.0M $193.0M $96.06M
YoY Change
Total Liabilities & Shareholders Equity $482.0M $216.4M $108.4M
YoY Change 392.63% 99.59%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$24.50M -$23.86M -$40.96M
YoY Change 106.34% -41.74% 44.56%
Depreciation, Depletion And Amortization $72.00K $79.00K $205.0K
YoY Change 0.0% -61.46% 3316.67%
Cash From Operating Activities -$21.73M -$20.56M -$34.09M
YoY Change 80.68% -39.7% 59.31%
INVESTING ACTIVITIES
Capital Expenditures $1.156M $820.0K $84.00K
YoY Change 1528.17% 876.19% -92.27%
Acquisitions
YoY Change
Other Investing Activities -$179.6M $30.95M -$72.37M
YoY Change -1824.82% -142.77% -505.07%
Cash From Investing Activities -$180.7M $30.13M -$72.45M
YoY Change -1847.84% -141.59% -531.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $31.53M
YoY Change -69.49%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 281.6M 473.0K 29.33M
YoY Change -89223.1% -98.39% -71.63%
NET CHANGE
Cash From Operating Activities -21.73M -20.56M -34.09M
Cash From Investing Activities -180.7M 30.13M -72.45M
Cash From Financing Activities 281.6M 473.0K 29.33M
Net Change In Cash 79.16M 10.04M -77.21M
YoY Change -4055.82% -113.01% -178.19%
FREE CASH FLOW
Cash From Operating Activities -$21.73M -$20.56M -$34.09M
Capital Expenditures $1.156M $820.0K $84.00K
Free Cash Flow -$22.89M -$21.38M -$34.18M
YoY Change 89.18% -37.45% 51.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
67018087
dei Entity Central Index Key
EntityCentralIndexKey
0001888886
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Other Liability Related Party Type Extensible Enumeration
OtherLiabilityRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Liability Related Party Type Extensible Enumeration
OtherLiabilityRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q3 us-gaap Other Liability Related Party Counterparty Name Extensible Enumeration
OtherLiabilityRelatedPartyCounterpartyNameExtensibleEnumeration
http://structuretx.com/20230930#SchrodingerInc.Member
CY2022Q4 us-gaap Other Liability Related Party Counterparty Name Extensible Enumeration
OtherLiabilityRelatedPartyCounterpartyNameExtensibleEnumeration
http://structuretx.com/20230930#SchrodingerInc.Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41608
dei Entity Registrant Name
EntityRegistrantName
Structure Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1480821
dei Entity Address Address Line1
EntityAddressAddressLine1
601 Gateway Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
628
dei Local Phone Number
LocalPhoneNumber
229-9277
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
139159315
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50636000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26091000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
154788000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
64750000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4535000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2248000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
209959000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
93089000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2408000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1031000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3653000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
262000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
350000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3463000
CY2023Q3 us-gaap Assets
Assets
216370000
CY2022Q4 us-gaap Assets
Assets
97845000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3319000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6009000
CY2023Q3 gpcr Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
15955000
CY2022Q4 gpcr Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
6741000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
817000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
260000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20091000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13010000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3034000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
281000
CY2023Q3 us-gaap Liabilities
Liabilities
23406000
CY2022Q4 us-gaap Liabilities
Liabilities
13010000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
375332000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1921000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-310000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-110000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182069000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116952000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
192964000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-115140000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
216370000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97845000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17515000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9160000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50061000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27833000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8630000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3533000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21720000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11772000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
26145000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
12693000
us-gaap Operating Expenses
OperatingExpenses
71781000
us-gaap Operating Expenses
OperatingExpenses
39605000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26145000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12693000
us-gaap Operating Income Loss
OperatingIncomeLoss
-71781000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39605000
CY2023Q3 gpcr Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
2688000
CY2022Q3 gpcr Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
349000
gpcr Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
7212000
gpcr Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
356000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23457000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12344000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-64569000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39249000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
405000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
73000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
548000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
197000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-23862000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-12417000
us-gaap Net Income Loss
NetIncomeLoss
-65117000
us-gaap Net Income Loss
NetIncomeLoss
-39446000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1515000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23862000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12417000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-65117000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40961000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.34
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114948000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114948000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9780000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9780000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100613000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100613000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9428000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9428000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
80000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-200000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-135000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
80000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-50000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-200000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-135000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23782000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12467000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65317000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39581000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-115140000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
199975000
CY2023Q1 gpcr Stock Issuance Costs And Underwriting Discount
StockIssuanceCostsAndUnderwritingDiscount
18586000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
166670000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2533000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
257000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17975000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
236351000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
179000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1702000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-537000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-23280000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
214415000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
473000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1858000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
80000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-23862000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
192964000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-64735000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
620000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-35000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13081000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-77231000
CY2022Q2 gpcr Temporary Equity Issuance Costs
TemporaryEquityIssuanceCosts
1515000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
1515000
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
6000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
643000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13948000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-92103000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
628000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-12417000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-103913000
us-gaap Profit Loss
ProfitLoss
-65117000
us-gaap Profit Loss
ProfitLoss
-39446000
us-gaap Share Based Compensation
ShareBasedCompensation
6093000
us-gaap Share Based Compensation
ShareBasedCompensation
1891000
us-gaap Depreciation
Depreciation
223000
us-gaap Depreciation
Depreciation
205000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
4000
gpcr Non Cash Lease Expense
NonCashLeaseExpense
444000
gpcr Non Cash Lease Expense
NonCashLeaseExpense
271000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3651000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
427000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2287000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
73000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-22000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2258000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2277000
gpcr Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
9012000
gpcr Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
1485000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-244000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-277000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57759000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34094000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
180768000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
114265000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
94181000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
41900000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1011000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-87598000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72449000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
172296000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
3077000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2197000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
31500000
gpcr Repurchases Of Unvested Restricted Share Awards
RepurchasesOfUnvestedRestrictedShareAwards
6000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
683000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
33000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
169902000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29330000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24545000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-77213000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26091000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105305000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50636000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28092000
gpcr Conversion Of Redeemable Convertible Preferred Shares Into Ordinary Shares Upon Initial Public Offering
ConversionOfRedeemableConvertiblePreferredSharesIntoOrdinarySharesUponInitialPublicOffering
199975000
gpcr Exchange Of Ordinary Shares To Non Voting Ordinary Shares
ExchangeOfOrdinarySharesToNonVotingOrdinaryShares
1000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
312000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3835000
us-gaap Asset Retirement Obligation Period Increase Decrease
AssetRetirementObligationPeriodIncreaseDecrease
277000
gpcr Deferred Offering Costs Included In Accounts Payable And Accrued Expenses And Other Current Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
312000
gpcr Deferred Offering Costs Included In Accounts Payable And Accrued Expenses And Other Current Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
36000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1515000
CY2023Q3 gpcr Number Of Ordinary Shares To Be Issued Upon Conversion
NumberOfOrdinarySharesToBeIssuedUponConversion
1
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182100000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
205400000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3401000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
313000
CY2023Q3 gpcr Accrued Income Taxes And Value Added Tax Payable Current
AccruedIncomeTaxesAndValueAddedTaxPayableCurrent
580000
CY2022Q4 gpcr Accrued Income Taxes And Value Added Tax Payable Current
AccruedIncomeTaxesAndValueAddedTaxPayableCurrent
174000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of expenses during the reporting periods. Such estimates include lease liability, accruals for research and development activities, ordinary share valuation and related share-based compensation and certain other accrued liabilities. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company is exposed to credit risk from its deposits of cash, cash equivalents and short-term investments in excess of the amount of insurance provided on such deposits. The Company invests its cash, cash equivalents and short-term investments in money market funds, corporate debt securities, U.S. government </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">bonds and U.S. government agency bonds. The Company limits its credit risk associated with cash, cash equivalents and short-term investments by investing in investment-grade securities and using banks and institutions it believes are creditworthy. The Company has not experienced any losses on its deposits of cash, cash equivalents and short-term investments to date. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</p>
CY2023Q3 us-gaap Deferred Costs
DeferredCosts
300000
CY2022Q4 gpcr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
438000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2980000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1380000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
572000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
349000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2408000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1031000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3386000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3544000
CY2023Q3 gpcr Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2564000
CY2022Q4 gpcr Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1818000
CY2023Q3 gpcr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4585000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1439000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
454000
CY2023Q3 gpcr Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
15955000
CY2022Q4 gpcr Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
6741000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
198817000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
83744000
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
199127000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
314000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
4000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
198817000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
83854000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
113000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
3000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
83744000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0
gpcr Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0
CY2022Q3 gpcr Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0
gpcr Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0
CY2023Q3 gpcr Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
93000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1326000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1341000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1287000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
359000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4406000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
555000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3851000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
817000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3034000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
600000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
400000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
1200000
us-gaap Operating Lease Cost
OperatingLeaseCost
800000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
800000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
600000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2023Q2 gpcr Area Of Property Subleased
AreaOfPropertySubleased
11800
CY2023Q2 gpcr Sub Lease Annual Base Rent
SubLeaseAnnualBaseRent
500000
CY2023Q2 gpcr Sub Lease Percentage Of Increase To Annual Base Rent
SubLeasePercentageOfIncreaseToAnnualBaseRent
0.03
CY2023Q2 gpcr Area Of Property Leased
AreaOfPropertyLeased
8400
CY2023Q2 gpcr Operating Lease Annual Base Rent
OperatingLeaseAnnualBaseRent
300000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
67018087
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
67018087
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
199975000
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
198016000
CY2023Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
67018087
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2023Q2 gpcr Beneficial Ownership Limitation Notice Period
BeneficialOwnershipLimitationNoticePeriod
P61D
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
977000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7612000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.62
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M25D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13283000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
12000000
gpcr Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted
-5102000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5102000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.11
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
430000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.60
gpcr Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited
390000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
390000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.39
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
8265000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11894000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M19D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
158863000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4160000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M18D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
64290000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11894000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y5M19D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
158863000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1700000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
400000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3500000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1100000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1858000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
628000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6093000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1891000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
28300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-23862000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-12417000
us-gaap Net Income Loss
NetIncomeLoss
-65117000
us-gaap Net Income Loss
NetIncomeLoss
-39446000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1515000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23862000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12417000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-65117000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40961000
CY2023Q3 gpcr Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
114948000
CY2022Q3 gpcr Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
10510000
gpcr Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
100700000
gpcr Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
10918000
CY2022Q3 gpcr Weighted Average Unvested Restricted Ordinary Shares Subject To Repurchase
WeightedAverageUnvestedRestrictedOrdinarySharesSubjectToRepurchase
730000
gpcr Weighted Average Unvested Restricted Ordinary Shares Subject To Repurchase
WeightedAverageUnvestedRestrictedOrdinarySharesSubjectToRepurchase
87000
gpcr Weighted Average Unvested Restricted Ordinary Shares Subject To Repurchase
WeightedAverageUnvestedRestrictedOrdinarySharesSubjectToRepurchase
1490000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114948000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114948000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9780000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9780000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100613000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100613000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9428000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9428000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.34
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11894000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
75032000

Files In Submission

Name View Source Status
0001558370-23-019203-index-headers.html Edgar Link pending
0001558370-23-019203-index.html Edgar Link pending
0001558370-23-019203.txt Edgar Link pending
0001558370-23-019203-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gpcr-20230930.xsd Edgar Link pending
gpcr-20230930x10q.htm Edgar Link pending
gpcr-20230930x10q001.jpg Edgar Link pending
gpcr-20230930xex10d4.htm Edgar Link pending
gpcr-20230930xex31d1.htm Edgar Link pending
gpcr-20230930xex31d2.htm Edgar Link pending
gpcr-20230930xex32d1.htm Edgar Link pending
gpcr-20230930xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
gpcr-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
gpcr-20230930_def.xml Edgar Link unprocessable
gpcr-20230930_lab.xml Edgar Link unprocessable
gpcr-20230930_pre.xml Edgar Link unprocessable
gpcr-20230930x10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending